Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Nurix Therapeutics (NRIX) Net Income towards Common Stockholders: 2019-2024

Historic Net Income towards Common Stockholders for Nurix Therapeutics (NRIX) over the last 6 years, with Nov 2024 value amounting to -$193.6 million.

  • Nurix Therapeutics' Net Income towards Common Stockholders fell 76.53% to -$86.4 million in Q3 2025 from the same period last year, while for Aug 2025 it was -$244.8 million, marking a year-over-year decrease of 38.32%. This contributed to the annual value of -$193.6 million for FY2024, which is 34.47% down from last year.
  • As of FY2024, Nurix Therapeutics' Net Income towards Common Stockholders stood at -$193.6 million, which was down 34.47% from -$143.9 million recorded in FY2023.
  • Nurix Therapeutics' Net Income towards Common Stockholders' 5-year high stood at -$43.2 million during FY2020, with a 5-year trough of -$193.6 million in FY2024.
  • Its 3-year average for Net Income towards Common Stockholders is -$172.6 million, with a median of -$180.4 million in 2022.
  • As far as peak fluctuations go, Nurix Therapeutics' Net Income towards Common Stockholders plummeted by 171.28% in 2021, and later rose by 20.19% in 2023.
  • Nurix Therapeutics' Net Income towards Common Stockholders (Yearly) stood at -$43.2 million in 2020, then slumped by 171.28% to -$117.2 million in 2021, then slumped by 53.90% to -$180.4 million in 2022, then grew by 20.19% to -$143.9 million in 2023, then tumbled by 34.47% to -$193.6 million in 2024.